# APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

> **NCT00343460** · PHASE3 · COMPLETED · sponsor: **Heron Therapeutics** · enrollment: 1428 (actual)

## Conditions studied

- Nausea and Vomiting
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** APF530
- **DRUG:** dexamethasone
- **DRUG:** Palonosetron Hydrochloride
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00343460
- **Lead sponsor:** Heron Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-09
- **Final completion:** 2009-02
- **Target enrollment:** 1428 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343460, "APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00343460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*